BOSTON—General Electric is selling its biopharma business to Danaher Corp. for $21.4 billion as it continues to sell off chunks of a once-sprawling conglomerate.
The biopharma unit, part of GE Life Sciences, generated revenue of about $3 billion last year. Danaher said after tax benefits, the deal will have a price tag that is closer a $20 billion. The mostly-cash transaction is expected to close in the fourth quarter of this year.
